Sarcoma
The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.
Although the results suggested the combination seems to have clinical activity, the researchers advised phase 3 trials are needed to confirm.
In this multicenter, randomized phase 2…
featured stories
View Conference Coverage
Take a look at some of our conference coverage, visit our roundup section.
Videos
-
May 19, 2020
ASCO - Retroperitoneal Sarcomas: the Benefits of…
-
May 19, 2020
Genetic Landscape of Soft-tissue Sarcomas
-
May 19, 2020
2019 ASCO Annual Meeting Research Round Up: Soft-…
Conference Roundup
- Nov 20, 2020
T-cell therapy shows durable response in soft tissue sarcoma
A durable response was found in patients with synovial sarcoma treated with ADP-A2M4 (Adaptimmune Therapeutics), according to data presented at the virtual Connective Tissue Oncology Society (CTOS) annual meeting.
Updated data from the phase 1 trial…
Journal Scan
- Jan 14, 2021
Gemcitabine/pazopanib combination shows clinical activity in soft-tissue sarcoma
The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.
…Trending Topics
- Nov 09, 2020
Anti-depressant repurposed to treat childhood cancer
A new study has found that a commonly prescribed anti-depressant may halt growth of a type of cancer known as childhood sarcoma, at least in mice and laboratory cell experiments. The findings, from researchers at Karolinska Institutet in Sweden and MD Anderson Cancer Centre in Texas, ignite hope…
